Search results for "Triglyceride"

showing 10 items of 444 documents

Associations between serum uric acid concentrations and metabolic syndrome and its components in the PREDIMED study.

2015

Several studies have demonstrated a relationship between increased serum uric acid (SUA) concentrations and the prevalence of metabolic syndrome (MetS) in the oriental population. However, to the best of our knowledge, the association between SUA and MetS has never been investigated in elderly European individuals at high cardiovascular risk. The aim of this study was to conduct a cross-sectional and prospective evaluation of the associations between SUA concentrations and the MetS in elderly individuals at high cardiovascular risk.Men and women (55-80 years of age) from different PREDIMED (Prevención con DIeta MEDiterránea) recruiting centers were studied. Baseline cross-sectional (n = 441…

MaleSíndrome metabòlicamedicine.medical_specialtyCross-sectional studyEndocrinology Diabetes and MetabolismPopulationMedicine (miscellaneous)0939-4753HyperuricemiaBioquímica i biotecnologiaBody Mass IndexAsian PeopleRisk FactorsInternal medicineSurveys and QuestionnairesPrevalenceMedicineHumansHyperuricemiaProspective StudieseducationProspective cohort studyAgedAged 80 and overHypertriglyceridemiaMetabolic SyndromeBioquímica y tecnologíaeducation.field_of_studyNutrition and Dieteticsbusiness.industryHazard ratioCholesterol HDLPREDIMED studyCholesterol LDLMiddle Agedmedicine.diseaseUric AcidBiochemistry and technologyCross-Sectional StudiesLogistic ModelsQuartileCardiovascular DiseasesHypertensionFemaleMetabolic syndromeCardiology and Cardiovascular MedicinebusinessBody mass indexFollow-Up StudiesNutrition, metabolism, and cardiovascular diseases : NMCD
researchProduct

Reduced circulating sTWEAK levels are associated with metabolic syndrome in elderly individuals at high cardiovascular risk

2014

BACKGROUND: The circulating soluble TNF-like weak inducer of apoptosis (sTWEAK) is a cytokine that modulates inflammatory and atherogenic reactions related to cardiometabolic risk. We investigated the association between sTWEAK levels and metabolic syndrome (MetS) and its components in older subjects at high cardiovascular risk. METHODS: Cross-sectional analysis of 452 non-diabetic individuals (men and women aged 55-80 years) at high cardiovascular risk. MetS was defined by AHA/NHLBI and IDF criteria. Logistic regression analyses were used to estimate odds ratios (ORs) for MetS and its components by tertiles of serum sTWEAK concentrations measured by ELISA. RESULTS: sTWEAK concentrations we…

MaleSíndrome metabòlicamedicine.medical_specialtyEpidemiologyRisk factors in diseasesCross-sectional studyEndocrinology Diabetes and MetabolismRenal functionInsulin resistanceRisk FactorsInternal medicineDiabetes mellitusmedicineHumansEpidemiologiasTWEAKAbdominal obesityOriginal InvestigationAgedAged 80 and overMetabolic SyndromeMalalties cardiovascularsFactors de risc en les malaltiesbusiness.industryBiochemical markersHypertriglyceridemiaCytokine TWEAKInsulin resistanceOdds ratioMiddle AgedCardiovascular riskmedicine.diseaseMetabolic syndromeCross-Sectional StudiesCardiovascular diseasesCardiovascular DiseasesTumor Necrosis FactorsMarcadors bioquímicsFemaleResistència a la insulinamedicine.symptomMetabolic syndromeCardiology and Cardiovascular MedicinebusinessBiomarkersCardiovascular Diabetology
researchProduct

Fenofibrate effect on triglyceride and postprandial response of apolipoprotein A5 variants: the GOLDN study.

2007

Objective— Apolipoprotein A5 ( APOA5 ) is a key determinant of plasma triglyceride (TG) concentrations. Genetic variation at the APOA5 locus could be responsible for some of the observed differences in response to fenofibrate therapy. Methods and Results— We examined the association between tag SNPs (−1131T>C and 56C>G) at APOA5 and TG and HDL-C response to fenofibrate and a postprandial lipid challenge in 791 men and women participating in the GOLDN study. After 3-week drug treatment, APOA5 56G carriers displayed significant decrease in TG ( P =0.006), and increase in HDL-C ( P =0.002) levels relative to their basal values in the fasting state when compared with noncarriers (a TG re…

MaleTime FactorsApolipoprotein BAdministration Oralchemistry.chemical_compoundFenofibrateGene FrequencyApolipoprotein a5Hypolipidemic AgentsAged 80 and overFenofibratebiologyMiddle AgedPostprandial PeriodPostprandialTreatment OutcomeArea Under CurveFemaleCardiology and Cardiovascular Medicinemedicine.drugAdultmedicine.medical_specialtyGuanineAdolescentGenotypeSingle-nucleotide polymorphismHyperlipidemiasPolymorphism Single NucleotideCytosineInternal medicinemedicineHumansParticle SizeApolipoproteins ATriglyceridesAgedTriglyceridebusiness.industryCholesterolCholesterol HDLCholesterol LDLDrug interactionLipid MetabolismDietary FatsUnited StatesEndocrinologychemistryApolipoprotein A-Vbiology.proteinbusinessThymineArteriosclerosis, thrombosis, and vascular biology
researchProduct

Endotoxin accelerates atherosclerosis independent of complement activation

2008

a Central Laboratory Animal Facility b Institute of Clinical Chemistry and Laboratory Medicine c Institute of Medical Microbiology and Hygiene, Johannes Gutenberg University, Mainz, Germany d Klinik fur Gefaschirurgie und Nierentransplantation, Heinrich Heine Universitatsklinik, Dusseldorf, Germany e Zentrum fur Medizin und Biowissenschaften, Forschungszentrum, Borstel, Germany f Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland g Department of Molecular Pathology, Graduate School of Medicine and Engineering, University of Yamanashi, Japan

MaleTime FactorsLibrary scienceHyperlipidemiasHematologyBiologyAtherosclerosisComplement C6Central laboratoryEndotoxinsC-Reactive ProteinCholesterolImmunologyAnimalsHumansFemaleRabbitsComplement ActivationTriglyceridesAnimal facilityThrombosis Research
researchProduct

The lipid-lowering effects of lomitapide are unaffected by adjunctive apheresis in patients with homozygous familial hypercholesterolaemia – A post-h…

2015

AbstractObjectiveLomitapide (a microsomal triglyceride transfer protein inhibitor) is an adjunctive treatment for homozygous familial hypercholesterolaemia (HoFH), a rare genetic condition characterised by elevated low-density lipoprotein-cholesterol (LDL-C), and premature, severe, accelerated atherosclerosis. Standard of care for HoFH includes lipid-lowering drugs and lipoprotein apheresis. We conducted a post-hoc analysis using data from a Phase 3 study to assess whether concomitant apheresis affected the lipid-lowering efficacy of lomitapide.MethodsExisting lipid-lowering therapy, including apheresis, was to remain stable from Week −6 to Week 26. Lomitapide dose was escalated on the basi…

MaleTime FactorsSettore MED/09 - Medicina InternaGastroenterologyMicrosomal triglyceride transfer proteinchemistry.chemical_compoundLipoprotein apheresisMedicineHyperlipoproteinemia Type IIHomozygous familial hypercholesterolaemia; Lipoprotein apheresis; Lomitapide; Adult; Anticholesteremic Agents; Benzimidazoles; Biomarkers; Blood Component Removal; Cholesterol LDL; Combined Modality Therapy; Female; Genetic Predisposition to Disease; Humans; Hyperlipoproteinemia Type II; Lipoprotein(a); Male; Phenotype; Time Factors; Treatment Outcome; Young Adult; Homozygote; Cardiology and Cardiovascular MedicinebiologyAnticholesteremic AgentsHomozygoteLipoprotein(a)Combined Modality TherapyCholesterolPhenotypeTreatment OutcomeBlood Component Removallipids (amino acids peptides and proteins)FemaleCardiology and Cardiovascular MedicineAdultmedicine.medical_specialtySocio-culturaleLipoprotein apheresiArticleLDLHyperlipoproteinemia Type IIYoung AdultHomozygous familial hypercholesterolaemiaInternal medicinePost-hoc analysisHumansGenetic Predisposition to DiseaseHomozygous familial hypercholesterolaemia; Lipoprotein apheresis; Lomitapide; Cardiology and Cardiovascular Medicinebusiness.industryCholesterol LDLLomitapideLomitapideEndocrinologyApheresischemistryConcomitantAdjunctive treatmentbiology.proteinBenzimidazolesbusinessBiomarkersLipoprotein(a)Atherosclerosis
researchProduct

TRIB1 constitutes a molecular link between regulation of sleep and lipid metabolism in humans.

2012

Epidemiological studies show association between sleep duration and lipid metabolism. In addition, inactivation of circadian genes induces insulin resistance and hyperlipidemia. We hypothesized that sleep length and lipid metabolism are partially controlled by the same genes. We studied the association of total sleep time (TST) with 60 genetic variants that had previously been associated with lipids. The analyses were performed in a Finnish population-based sample (N = 6334) and replicated in 2189 twins. Finally, RNA expression from mononuclear leucocytes was measured in 10 healthy volunteers before and after sleep restriction. The genetic analysis identified two variants near TRIB1 gene th…

MaleTwinsBlood lipidsGene ExpressionCohort Studies0302 clinical medicineGene FrequencySleep and metabolismHomeostasisgeneticsta515FinlandSlow-wave sleepSleep restriction2. Zero hunger0303 health sciencesIntracellular Signaling Peptides and Proteinsta3141Middle AgedSleep in non-human animals3142 Public health care science environmental and occupational health3. Good healthPsychiatry and Mental healthFemaleOriginal Articleepidemiologymedicine.symptomAdultmedicine.medical_specialtyGenotypeSNPDisorders of Excessive SomnolenceBiologyProtein Serine-Threonine Kinasesta3111Polymorphism Single Nucleotidelipids03 medical and health sciencesCellular and Molecular NeuroscienceInternal medicinemedicineHumansCircadian rhythmsleepBiological PsychiatryAllelesGenetic Association StudiesTriglycerides030304 developmental biologyAgedCholesterol HDLGenetic VariationLipid metabolismCholesterol LDLLipid Metabolismta3124Sleep deprivationEndocrinologySleep Deprivationmetabolism030217 neurology & neurosurgeryTranslational psychiatry
researchProduct

Fatty liver in familial hypobetalipoproteinemia: triglyceride assembly into VLDL particles is affected by the extent of hepatic steatosis

2003

Familial hypobetalipoproteinemia (FHBL) subjects may develop fatty liver. Liver fat was assessed in 21 FHBL with six different apolipoprotein B (apoB) truncations (apoB-4 to apoB-89) and 14 controls by magnetic resonance spectroscopy (MRS). Liver fat percentages were 16.7 +/- 11.5 and 3.3 +/- 2.9 (mean +/- SD) (P = 0.001). Liver fat percentage was positively correlated with body mass index, waist circumference, and areas under the insulin curves of 2 h glucose tolerance tests, suggesting that obesity may affect the severity of liver fat accumulation in both groups. Despite 5-fold differences in liver fat percentage, mean values for obesity and insulin indexes were similar. Thus, for similar…

MaleVery low-density lipoproteinSettore MED/09 - Medicina InternaApolipoprotein Bmedicine.medical_treatmentPalmitic AcidLipoproteins VLDLSeverity of Illness IndexTriglyceridevery low density lipoprotein assemblyBiochemistryBody Mass IndexMagnetic resonence spectroscopy; Nonalcoholic fatty liver; Nonesterified fatty acids; Very low density lipoprotein assembly; Adult; Body Mass Index; Dietary Fats; Fatty Liver; Female; Glucose Tolerance Test; Humans; Hypobetalipoproteinemias; Insulin Resistance; Lipoproteins VLDL; Liver Diseases; Male; Middle Aged; Obesity; Palmitic Acids; Severity of Illness Index; Triglycerides; EndocrinologyHypobetalipoproteinemiaschemistry.chemical_compoundEndocrinologyDietary FatGlucose tolerance testmedicine.diagnostic_testbiologyChemistryLiver DiseasesLiver DiseaseFatty liverMiddle AgedFemalemagnetic resonence spectroscopyHumanAdultmedicine.medical_specialtyPalmitic Acidsnonesterified fatty acidsQD415-436Internal medicinemedicinenonalcoholic fatty liverHumansObesityTriglyceridesTriglycerideInsulinNonesterified fatty acidCell BiologyGlucose Tolerance Testmedicine.diseaseDietary FatsFatty LiverEndocrinologybiology.proteinHypobetalipoproteinemiaInsulin ResistanceSteatosisHypobetalipoproteinemiaJournal of Lipid Research
researchProduct

Changes in Serum and Lipoprotein Fatty Acids of Growing Rats Fed Protein-Deficient Diets with Low or Adequate Linolenic Acid Concentrations

1992

The effects of a protein-deficient diet associated with sunflower oil [adequate in 18:2(n-6), poor in 18:3(n-3)] or soybean oil [adequate in both 18:2(n-6) and 18:3(n-3)] on lipid serum and lipoprotein compositions were studied in growing rats. Four groups of rats were fed different diets: SFC (20% casein + 5% sunflower oil); SFd (2% casein + 5% sunflower oil); SC (20% casein + 5% soybean oil); Sd (2% casein + 5% soybean oil). After 28 d, both protein-deficient groups exhibited low concentrations of protein, phospholipid, triacylglycerol and total cholesterol in serum and VLDL. Compared with rats fed 20% casein diets, those fed low protein diets had lower 18:2(n-6) and 20:4(n-6) in phosphol…

MaleVery low-density lipoproteinmedicine.medical_specialtyfood.ingredientLow proteinLinolenic AcidsLinolenic acidLipoproteinsMedicine (miscellaneous)Lipoproteins VLDLBiologySoybean oilfoodProtein DeficiencyInternal medicineCaseinmedicineAnimalsFood sciencePhospholipidsTriglycerideschemistry.chemical_classificationNutrition and DieteticsSunflower oilFatty AcidsFatty acidRats Inbred StrainsRatsEndocrinologychemistryHelianthuslipids (amino acids peptides and proteins)SoybeansLipoproteins HDLPolyunsaturated fatty acidThe Journal of Nutrition
researchProduct

Vitamin A Deficiency Increases Protein Catabolism and Induces Urea Cycle Enzymes in Rats

2010

Chronic vitamin A deficiency induces a substantial delay in the rates of weight and height gain in both humans and experimental animals. This effect has been associated with an impaired nutrient metabolism and loss of body protein. Therefore, we analyzed the effect of vitamin A deficiency on endogenous proteolysis and nitrogen metabolism and its reversibility with all-trans retinoic acid (RA). Male weanling rats, housed in pairs, were pair-fed a vitamin A-deficient (VAD) or control diet until they were 60 d old. A group of deficient rats were further treated with daily intraperitoneal injections of all-trans RA for 10 d. Final body and tissue (i.e. liver and heart) weights were significantl…

MaleVitaminmedicine.medical_specialtyNitrogenMedicine (miscellaneous)TretinoinBiologyAntioxidantsRetinoidschemistry.chemical_compoundInternal medicinemedicineAnimalsUreaMuscle SkeletalTriglyceridesNutrition and DieteticsVitamin A DeficiencyCatabolismRetinolProtein turnoverMethylhistidinesmedicine.diseaseRatsVitamin A deficiencyProtein catabolismEndocrinologyLiverchemistryEnzyme InductionUrea cycleLipid PeroxidationEnergy sourceThe Journal of Nutrition
researchProduct

Relative Telomere Length and Cardiovascular Risk Factors

2019

(1) Background: Telomeres are repetitive DNA sequences located at the extremities of chromosomes that maintain genetic stability. Telomere biology is relevant to several human disorders and diseases, specifically cardiovascular disease. To better understand the link between cardiovascular disease and telomere length, we studied the effect of relative telomere length (RTL) on cardiovascular risk factors in a large population-based sample. (2) Methods: RTL was measured by a real-time quantitative polymerase chain reaction in subjects of the population-based Gutenberg Health Study (n = 4944). We then performed an association study of RTL with known cardiovascular risk factors of smoking status…

Malecardiovascular risk factorsmedicine.medical_specialtyCardiovascular risk factorsPopulationlcsh:QR1-502Disease030204 cardiovascular system & hematologyBiochemistryArticlelcsh:MicrobiologyBody Mass Index03 medical and health scienceschemistry.chemical_compound0302 clinical medicinecardiovascular diseaseInternal medicinetelomere lengthHumansMedicine030212 general & internal medicineeducationMolecular BiologyTriglyceridesAgededucation.field_of_studybusiness.industryCholesterolSmokingAge FactorsTelomere HomeostasisMiddle AgedtelomeresTelomereCholesterolEndocrinologyBlood pressurechemistryCardiovascular DiseasesageingAgeingFemalebusinessBody mass indexBiomolecules
researchProduct